Gossamer Bio, Inc.'s (NASDAQ:GOSS) Executive Vice President of Regulatory Affairs, Caryn Peterson, has recently sold a portion of her company shares, according to the latest filings. On March 18, Peterson sold 4,018 shares of Gossamer Bio at a weighted average price of $1.3297, totaling approximately $5,342.
The transaction was broker-assisted and was conducted to satisfy tax withholding obligations related to the vesting of restricted stock units. The sale was executed in multiple trades, with prices ranging from $1.329 to $1.335 per share. Following the sale, Peterson's remaining stake in the company amounts to 49,833 shares of common stock.
Investors interested in the specifics of the share prices for each trade can request detailed information directly from Gossamer Bio. The sale represents a common practice among executives to manage their stock-based compensation and the associated tax implications.
Gossamer Bio, headquartered in San Diego, California, operates in the pharmaceutical preparations industry and specializes in developing innovative therapies. The company's shares are publicly traded on the NASDAQ stock exchange under the ticker symbol GOSS. As with all insider transactions, the sale by Peterson has been publicly disclosed in compliance with SEC regulations, providing transparency to investors and the market.
InvestingPro Insights
Amid the recent insider trading activity, Gossamer Bio, Inc. (NASDAQ:GOSS) presents a mix of financial metrics and market performance that investors should consider. According to InvestingPro data, Gossamer Bio holds a market capitalization of $311.3 million, reflecting its current valuation in the market. Despite a challenging financial performance with an operating income of approximately -$173.76 million over the last twelve months as of Q4 2023, the company has experienced significant price total returns. The 1-month, 3-month, and 6-month price total returns stand at 28.7%, 54.44%, and 48.97%, respectively, demonstrating a strong recent uptrend in its stock price.
InvestingPro Tips for Gossamer Bio highlight the company's volatile stock price movements and its lack of profitability in the last year. Analysts do not anticipate the company will be profitable this year, which is reflected in the negative P/E ratio of -1.74. Yet, the company has managed to maintain more cash than debt on its balance sheet, and its liquid assets exceed short-term obligations, suggesting a degree of financial stability. Additionally, the stock has shown a strong return over the last month and has seen a large price uptick over the last six months.
For investors seeking a deeper analysis and more InvestingPro Tips on Gossamer Bio, they can explore further insights at https://www.investing.com/pro/GOSS. There are 10 additional tips available on InvestingPro, which could provide a more comprehensive understanding of the company's financial health and market performance. Remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, enhancing your investment research with valuable tools and insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.